cyrilzakka/clinical-trials huggingface dataset:
Pulsed Dye Laser Treatment of Acne Vulgaris

The results of pulsed dye laser (PDL) treatment of acne vulgaris published so far are controversial: Whereas Seaton et al. described a marked improvement of mild-to-moderate acne after low-fluence pulsed-dye laser therapy, Orringer et al. were unable to replicate said results in a similar, albeit not identical, study design. More recently published studies failed to resolve the controversy, varying in terms of treatment procedure(s) as well as results.

While published results are certainly promising enough to be followed up by independent research, they are insufficient to justify the abdication of methods with proven efficacy. Considering patient treatment ethics and the short 'window of opportunity' for scar prevention when active inflammatory lesions are present, the investigators planned the adjuvant application of the PDL in the present study, providing all patients with the well established and evidentially effective modality of a fixed-combination clindamycin 1%-benzoyl peroxide 5% hydrating gel (C/BPO). The goal of the study was the assessment of the efficacy and safety of a low-fluence PDL treatment in addition to C/BPO in patients with facial inflammatory acne.


Eligibility Criteria:
Inclusion Criteria:

* Adolescents and adults with moderate inflammatory acne vulgaris (ISGA degrees 2-4)
* Fitzpatrick skin type I-III

Exclusion Criteria:

* Atopic dermatitis
* Oral antibiotics during the last 4 weeks prior to enrolment
* Oral isotretinoin during the last 52 weeks prior to enrolment
* Oral contraceptives during the last 26 weeks prior to enrolment
* Topical acne therapeutics during the last 4 weeks prior to enrolment
* Diagnosis or anamnestic indication of a regional enteritis, Morbus Crohn or antibiotics-associated colitis
* Laser surgery interventions within the treatment region during the last 12 weeks prior to enrolment
* Coagulation anomalies or anticoagulant treatment
* Photo-sensitizing medication (e. g., tetracycline, gold)
* Pregnancy
Lumbosacral Erector Spinae Plane Block Versus Psoas Muscle Compartment With Sciatic Nerve Block for Anesthesia for Unilateral Lower Limb Operations in Critically Ill Patients

This study aims to compare lumbosacral erector spinae plane block and psoas muscle compartment with sciatic nerve block in unilateral lower limb operations in critically ill patients.

The lower limb surgeries are associated with acute postoperative pain and require long-term analgesia. Regional anesthesia is often used to prevent postoperative pain. Ultrasound-guided regional anesthetic approaches provide a simple intraoperative pathway that lowers pain scores with less impact on the respiratory or cardiovascular system.

Psoas compartment block (PCB) is a peripheral regional technique of anesthesia, which provides a block of the main components of the lumbar plexus - the femoral, lateral cutaneous nerve of the femur and sciatic nerve. In combination with the sciatic nerve block, the psoas compartment block provides effective anesthesia of the entire lower extremity, with better hemodynamic stability.

The erector Spinae plane block (ESPB) is a novel regional block technique primarily introduced in 2016 for managing severe neuropathic pain.

Eligibility Criteria:
* Age from 18 to 65 years.
* Both sexes.
* American Society of Anesthesiology (ASA) physical status III, IV.
* Critically ill patients admitted to intensive care unit.
* Undergoing unilateral lower limb operations.

Exclusion Criteria:

* History of allergy to local anesthetics.
* Bleeding tendency.
* Coagulopathy.
* Anticoagulant therapy.
* Pre-existing psychological, neurologic, and spinal cord diseases.
* Previous back surgery.
* Infection or mass at the site of the block.
* Chronic analgesic therapy.
* Severe cardiac or renal diseases.
Towards Optimal Treatment of Marfan Syndrome

The purpose of this study is to determine whether new magnetic resonance imaging techniques can be used as a biomarker of aortic disease severity in patients with Marfan syndrome.


Eligibility Criteria:
Inclusion Criteria:

* MFS patients with a known FBN1 mutation
* Between 18-50 years of age

Exclusion Criteria:

* Contraindication for MR imaging
* Mental retardation
* Pregnancy, or planned pregnancy during study period

Additional exclusion criteria healthy controls:

- History of aorta disease
Haploinsufficiency of the RBM22 and SLU7 Genes in Del(5q) Myelodysplastic Syndromes

Myelodysplastic syndromes (MDS) are malignant hematopathies of the elderly characterized by persistent cytopenias and the presence of deregulated clonal hematopoiesis. The risk of progression to acute myeloid leukemia (AML) is variable. Acquired cytogenetic abnormalities are found in less than 50% of de novo cases and up to 80% in secondary MDS. The deletion of the long arm of chromosome 5 (written del(5q)) is the most common abnormality in MDS (15%). Del(5q) MDS has a good prognosis, with a median survival of 6 years and a 15% risk of progression to AML. However, their life expectancy is shorter than the general population, and the quality of life of patients is diminished. These treatments are not that effective over a long period of time or not well tolerated, and the majority of patients die from causes related to their MDS, such as infections (38%), progression to AML (15%), or bleeding (13%). Two genes, RBM22 and SLU7, coding for proteins of the same complex involved in splicing pre-messenger RNA are carried on the long arm of chromosome 5. We investigate the pronostic impact and the predictive value of the double haploinsufficiency of the RBM22 and SLU7 genes in del(5q) myelodysplastic syndromes isolated or not compared to the single haploinsufficiency of RBM22 and normal karyotype myelodysplastic syndromes.


Eligibility Criteria:
Inclusion Criteria:

* Patients diagnosed with del5q MDS isolated or not
* The clinical and biological data are known at the time of diagnosis.
* The clinical and biological data are known 1 year after the diagnosis
* Consent for the collection of samples for research purposes
* Non-opposition obtained

Exclusion Criteria:

* Patients under judicial protection (guardianship, ...)
* Refusal to participate
A Multicenter and Real-world Analysis of RC48-ADC in Patients With HER2-positive or HER2-low Expressing, Locally Advanced or Metastatic Breast Cancer

Evaluate the efficacy and safety of Disitamb Vedotin in patients with HER2-positive or HER2-low expressing, locally advanced or metastatic breast cancer

The main goal of this clinical trial is to examinie the utilization of RC48 in different HER2 statuses, elucidating its clinical outcomes and safety, and investigating the factors that influence its clinical efficacy. The primary endpoint was the objective response rate (ORR) assessed by the primary researcher. Secondary endpoints included progression-free survival (PFS), overall survival (OS), disease control rate (DCR), time to progression, and safety.

Eligibility Criteria:
Inclusion Criteria:

1. histopathologically or imaging-confirmedlocally advanced or metastatic breast cancer ;
2. HER2-positive or low status;
3. the function of major organswas normal, no treatmentcontraindications , andthe estimated survival time was more than 2 months;
4. at least one extracranialmeasurable lesion or osteolytic or mixed bone metastases inaccordance with the Response Evaluation Criteria in Solid Tumors v. 1.1 (RECIST 1.1);
5. the clinical data were complete and traceable.

Exclusion Criteria:

1. age \<18 ye ars old;
2. other concurrent cancers;
3. patients who rece ived RC48 as a neoadjuvant or adjuvant regimen；
4. Incomplete medical data.
Acetylsalicylic Acid Plus Intensive Blood Pressure Treatment in Patients With Unruptured Intracranial Aneurysms

Purpose of this study is to assess the hypothesis that a strategy with acetylsalicylic acid (ASA) 100 mg/day, intensive blood pressure treatment (targeted systolic blood pressure below 120 mmHg), and a blood pressure measuring device reduces the risk of aneurysm rupture or growth compared with standard care (i.e. no ASA, blood pressure management according to standard blood pressure management, no blood pressure measuring device)


Eligibility Criteria:
Inclusion Criteria:

* Patients 18 years or older with an intradural, saccular unruptured aneurysm (UIA) in whom it is decided not to intervene with preventive endovascular or neurosurgical repair of the aneurysm and who are monitored on a regular base for aneurysm growth
* Last aneurysm imaging with either CTA/MRA/DSA within the last 3 months

Exclusion Criteria:

* All non-saccular UIAs or aneurysms related to arteriovenous malformations
* Frequent ASA use and/or indication for a vitamin K antagonist, or direct oral anticoagulant (DOAC) treatment at baseline
* Contra-indication for ASA
* History of hypersensitivity to ASA or to any other drug with similar chemical structure or to any excipient present in the pharmaceutical form of ASA
* Chronic kidney disease stage IV and V (GFR \< 30 mL/min/1.73 m2)
* Pregnancy and lactation
* Participation in another clinical trial or observation period of competing trials, respectively
* Life-expectancy \<3 years
Effect of Methyldopa on Uterine Artery Diameter in Pregnant Women With Mild Preeclampsia

The present study examined the effects of Methyldopa on uterine artery diameter, uterine artery blood flow, umbilical artery and fetal middle-cerebral artery in patients with Preeclampsia, using Doppler ultrasound.


Eligibility Criteria:
They met the inclusion criteria, If they had over 25 weeks of gestational age, no history of chronic hypertension, no diabetes mellitus, no chronic systemic diseases, no collagen vascular diseases and antiphospholipid syndromes, no use of antihypertensive drugs and BMI higher than 19 and lower than 30 (kg/m2).
Targeting Obesity to Optimize Health in Cardiac Rehab (TOPCARE)

Although coronary heart disease (CHD) treatment guidelines recognize obesity as a major modifiable risk factor,2 nearly half of all CHD patients are obese and the current standard of care fails to implement evidence-based obesity treatment for this high-risk population. Multiple lines of evidence suggest that weight loss improves outcomes in CHD patients. The primary goal of this study is to determine the feasibility of adding a 6-month behavioral weight loss intervention to exercise-based cardiac rehabilitation.

Although coronary heart disease (CHD) treatment guidelines recognize obesity as a major modifiable risk factor,2 nearly half of all CHD patients are obese and the current standard of care fails to implement evidence-based obesity treatment for this high-risk population. The efficacy of exercise-based cardiac rehabilitation for improving exercise capacity and CHD risk factors is markedly blunted in CHD patients with obesity. Current programs largely focus on nutrient intake and produce minimal weight loss, on average. Our data show that despite appropriate exercise prescription and adherence, only 22% of CHD patients with obesity lose even the minimum recommended body weight over a 3-month program. These findings indicate that targeting reductions in caloric intake is needed to optimize outcomes in these patients and suggest that current programs are too short to produce adequate weight loss and ensure the necessary behavioral adaptations for long-term maintenance. Randomization to diet-induced weight loss in combination with aerobic exercise improves exercise capacity, quality of life, and CHD risk factors more than exercise alone and reduces long-term mortality in overweight and obese adults. The primary goal of this study is to determine the feasibility of adding a 6-month behavioral weight loss intervention to exercise-based cardiac rehabilitation.

Eligibility Criteria:
Inclusion Criteria:

* documented CHD defined as hospitalization for MI/heart attack coronary artery bypass grafting (CABG) or percutaneous coronary intervention (i.e., angioplasty, stent)
* age = 40 and older
* overweight or obese based on an elevated BMI (≥25 kg/m2)

Exclusion Criteria:

* body weight \>450 lbs
* congestive heart failure (ejection fraction \<35%)
* advanced kidney disease (on dialysis, or dialysis anticipated within 6 months)
* cognitive impairment (Montreal Cognitive Assessment \[MoCA\] score \<22)
* major depression (Patient Health Questionnaire \[PHQ-9\] ≥20)
* severe pulmonary disease (i.e., oxygen-dependent)
* significant impairment from a prior stroke or other neurologic disease or injury
* high risk for non-adherence (i.e., unwilling or unable to comply with study requirements)
* current participation in physical therapy or another weight loss study
* current or recent use of weight loss medications (e.g., orlistat)
* prior weight loss procedure
* drug/substance abuse or excessive alcohol (\> 14 drinks per week) within the past 6 months
* pregnant or pre-menopausal women
* peanut allergy
* milk allergy/lactose intolerance
Efficacy of an Educational School-based Intervention to Reduce Prevalence of Obesity in Childhood-EdAl-2

Our hypothesis is that a regular systematic educational intervention in primary school improves lifestyle choices and reduces obesity. As such, the aim of the study is to evaluate the effects of a 3-year school-based program of lifestyle improvement, including diet and physical activity, implemented by university students acting as "health promoting agents" (HPA) on the prevalence of obesity.

Initial pupil enrollment and continued for 3 years.

Eligibility Criteria:
Inclusion Criteria:

* In the intervention group, all children of the selected classroom are exposed to the intervention.
* The data a will collected on all the children, but only the data from individuals (and their parents) who provided informed consent are included in the final analyses.
* Name, gender, date and place of birth are recorded at the start of the program, while weight, height, body mass index (BMI) and waist circumference variables (identified set of anthropometric measures) are recorded in each of the 3 academic years of the study.

Exclusion Criteria:

* No adequate age
* Lack of inclusion criteria
Physical Fitness Training in Subacute Stroke (PHYS-Stroke)

The aim of this study is to investigate whether a 4-week physical fitness training (target intervention) in stroke patients (subacute stage) increase the walking speed and activities of daily living compared with a control intervention (relaxation exercises). The target or control intervention is performed in addition to standard rehabilitation treatment.


Eligibility Criteria:
Inclusion Criteria for patients:

* diagnosis of stroke within 5-45 days after stroke
* age \>= 18 years
* able to sit for at least 30 seconds
* Barthel index \< =65 at inclusion
* considered able to perform aerobic exercise as determined by responsible physician
* Written informed consent of the patient

Exclusion Criteria:

* Patient considered unable to comply with study requirements
* stroke due to intracranial hemorrhage primarily due to bleeding from ruptured aneurysm or arteriovenous malformation
* patients with progressive stroke
* unable to perfom the required exercises due to

  1. medical problems
  2. musculo-skeletal problems
  3. neurological problems
* required help to at least 1 persons to walk before stroke due to neurological or non-neurological co-morbidities
* life expectancy of less than 1 year as determined by responsible physician
* alcohol or drug addiction within the last 6 months
* significant current psychiatric illness as defined as medication-refractory of bipolar affective disorder, psychosis, schizophrenia or suicidality
* current participation in another intervention study
Visual Exploration and Attention: Studies in Patients With Schizophrenia and Autism Spectrum Disorders

The aim of the protocol is to better understand the impairments in visual processing, as such impairments may induce social interaction difficulties in subjects with autism spectrum disorders (adults and children) and schizophrenia, like face exploration.The same protocol will be used for the three populations, each population being compared with matched controls. The explorations are designed to test two different hypotheses regarding the mechanisms of the visual perception difficulties of the two populations. Even though difficulties to extract the global form of objects have been described in both subjects with autism and schizophrenia, we will test two different hypotheses for the two populations. We will test the hypothesis that subjects with autism display an advantage for the processing of local information arising at an early level of processing, whereas disorders observed in patients with schizophrenia originate from attention disorders. The protocol includes three consecutive studies, each one being applied in each of the three populations.


Eligibility Criteria:
Inclusion Criteria:

* IQ above 70, as evaluated with the WAIS III in adults and with the WISC in children
* signed consent
* DSM IV criteria in case of autism spectrum disorders or schizophrenia

Exclusion Criteria:

* grave or non stabilized somatic pathology
* pathology affecting the central nervous system; other than the studied pathologies
* intake of psychotropic drug, except for patients
* invalidating sensory processes
Prognostic Biomarkers of Pancreatic Cancer Based on Proteomics Techniques

In this study, we will use high-throughput proteomics techniques to search for biomarkers of post-operative prognosis of pancreatic cancer in samples of patients who have been diagnosed with pancreatic cancer through bioinformatics analysis.

This study plan from the affiliated hospital of Qingdao university collected 20 cases of patients with pancreatic cancer pathological tissue samples and clinical data, including clinical diagnostic information, laboratory tests, imaging examination results and other information data), through high-throughput proteomic technology in pancreatic cancer pathological finding biomarkers, the bioinformatics analysis to explore the prognosis biomarkers.

Eligibility Criteria:
Inclusion Criteria:

* Patients of Chinese nationality, age and gender are not limited.
* Pathologically confirmed pancreatic cancer patients.
* Pathological specimens were archived tumor tissue samples after a diagnosis of pancreatic cancer.
* Clinical diagnostic information was complete three months before sampling.

Exclusion Criteria:

* Patients with a second primary tumor.
Environmental Exposures and Sudden Unexpected Infant Death

This project is a descriptive study designed to identify the exposure of infants who died of MIN to ambient air pollutants, and to measure pesticide concentrations in biological matrices (hair, serum, LCS) within a sample from the OMIN registry. French national registry of STUDY of Sudden Unexpected Infant Death.

This project is a descriptive study designed to estimate the exposure of infants who died of MIN to ambient air pollutants, and to measure pesticide concentrations in biological matrices (hair, serum, LCS) within a sample from the OMIN registry. These two types of pollutants represent two important determinants of environmental health. Although their emission sources and chemical composition differ, these pollutants carry the risk of multiple toxicities that can contribute to the occurrence of Unexpected Infant Death Syndrome (SUID), and are widely present in France, in the air as well as in food, waterways, soils, etc. These two approaches have enabled us to develop two complementary methodologies: geostatistics associated with environmental epidemiology for air pollutants, and analytical environmental chemistry for pesticides.

In addition to matching these exposure measurements with data from the OMIN registry, we will be able to address the impact and determinants of these exposures - i.e., to highlight the individual and collective characteristics that favor high exposure, and to address the toxicological mechanisms linked to these exposures and that may contribute to the occurrence of SUID in general.

Eligibility Criteria:
Inclusion Criteria:

* Died and include in French registry of sudden infant death syndrome

Exclusion Criteria:

* None
Impact of Milk Polar Lipids on Lipids Digestion, Absorption and Metabolism

Polar lipids have a specific chemical structure: they are an essential component of human cell membranes, play a major role in the nervous system and also influence the metabolic pathways including the cholesterol metabolism.

Polar lipids are used in food-processing industry for their emulsification properties. The most famous emulsifier is soya lecithin but milk also naturally contains natural emulsifiers such as polar lipids. Milk polar lipids are rich in sphingomyelin and they may have beneficial effects on lipid metabolism in the context of metabolic diseases of nutritional origin.

The purpose of this research is to study the variation of sphingomyelin content at the ileum's end after the consumption of different doses of milk polar lipids, and consequences on the intestinal absorption and metabolism of fatty acids and cholesterol.

The subjects will be taking three different test meals varying by their milk polar lipids content.

It is a bi-centric study with a centre in LYON (Centre de Recherche en Nutrition Humaine Rhône-Alpes) and CLERMONT-FERRAND (Centre de Recherche en Nutrition Humaine Auvergne).


Eligibility Criteria:
Inclusion Criteria:

* Men and women aged between 18 and 75 years
* Having undergone a temporary or permanent ileostomy,
* Considered to have well-functioning ileostomy
* Normal (or not clinically significant) lipid parameters

Exclusion Criteria:

* Ileostomy due to an ongoing digestive cancer
* Ileostomy due to a Chrohn's disease
* Dairy products allergy or intolerance
* Medication that could interfere with lipid metabolism
Encouraging Allergic Young Adults to Carry Epinephrine

Fifteen million Americans suffer from food allergies. Food allergies can be life threatening; the only known life-saving treatment is epinephrine. Adolescents/young adults are at increased risk of adverse events, because of increased risk-taking with food and decreased likelihood of carrying epinephrine. This is a pilot randomized trial to test text message reminders, with and without financial incentives, to encourage allergic young adults to carry epinephrine.

Aim: We pilot tested a novel strategy to encourage young adults with food allergies to carry their epinephrine auto-injectors. Adolescents/young adults are at increased risk of adverse events, because of increased risk-taking with food and decreased likelihood of carrying epinephrine.

Study design: This is a pilot randomized controlled trial, with a survey component. Text messaging is the mode of communication and inquiry with study participants.

Hypothesis: The intervention group, which will receive modest financial incentives for carrying epinephrine, will be more likely to demonstrate that they are carrying their epinephrine, when queried by the study team.

This study employs text messaging, along with photography, as a mode of momentary ecologic assessment, or real-time measurement of epinephrine carrying. In addition, text messaging was used as a mode of asking questions regarding food allergy knowledge and beliefs among young adults. Text messages were sent from a designated telephone (and telephone number) purchased for use in this study. We used text messaging for reminder messages, text responses, and for the participants to send photographs back to us. We converted text message data (participants responses) into a RedCap database. Our research coordinator sent and received the text messages and compiled a secure RedCap database of responses.

Eligibility Criteria:
Inclusion Criteria:

* Have known food allergy
* Epinephrine auto-injector prescription
* Access to a cell phone with ability to send picture messages

Exclusion Criteria:

-